Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The onset of the therapeutic response to antidepressant treatment exhibits a characteristic delay. Animal models sensitive to chronic, but not acute, antidepressant treatment are greatly needed for studying antidepressant mechanisms. We initially assessed four inbred mouse strains for their behavioral response to chronic treatment with the selective-serotonin reuptake inhibitor fluoxetine (0, 5, 10 mg/kg/day in drinking water), which is used for the treatment of mood and anxiety disorders. Only the highly anxious BALB/c strain exhibited sensitivity to fluoxetine in the forced swim test. Additionally, fluoxetine reduced locomotion in C57BL/6 and 129SvEv, but not BALB/c and DBA/2, strains. We then evaluated the effects of subchronic (approximately 4 days) and chronic (approximately 24 days) fluoxetine treatment (0, 10, 18, 25 mg/kg/day) on measures of anxiety and depression in BALB/c mice. Anxiety measures were obtained using the open field and novelty-induced hypophagia tests. Antidepressant effects were evaluated using the forced swim test. We found 18 mg/kg/day of chronic fluoxetine to be active in all three paradigms; subchronic treatment had no effect. Anxiety-related measures were reduced by 18 mg/kg/day. In the forced swim test, 10 and 18 mg/kg/day increased swimming and reduced immobility. Here we present several novel effects of chronic, but not subchronic, antidepressant treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dosage of 18 mg/kg/day have been shown to be in the upper range of the therapeutic dose of fluoxetine administered to humans.16”
From Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression (2025) · cites this paper as [16]
In the citing paper
“Hyponeophagia (novelty-suppressed feeding) has also been used to assess anxiety-like behavior in rodents; in a novel environment, hungry mice exhibit an increased latency to feed that is sensitive to benzodiazepines and SSRIs47,48.”
From Resolving the neural circuits of anxiety (2015) · cites this paper as [47]
In the citing paper
“The NIH paradigm is a sensitive measure for potential anxiolytic drugs and anxiogenic effects of withdrawal on both acute and extended drug administration paradigms (Dulawa et al., 2004;Dulawa and Hen, 2005).”
From Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors (2014) · cites this paper as Dulawa et al., 2004
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“We have previously shown that steady state for both fluoxetine and norfluoxetine is achieved by 5 days of receiving fluoxetine in the drinking water (10 mgskgsday), as serum levels after 5 or 90 days of treatment are equivalent (”
BackgroundSelf-citationBehavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 4,013
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review
Prut, L., & Belzung, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01272-x · Cited by 3,175
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 1×
“The intake of palatable fluids, including sucrose and saccharin solutions, has been used as a measure of reward sensitivity (”
MethodAssessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551
Psychopharmacology: The Fourth Generation of Progress
Green, A. I. (1996) · Psychiatric Services · doi:10.1176/ps.47.3.312 · Cited by 1,145
Neuropsychopharmacology: The Fifth Generation of Progress
SAGDUYU, K. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1251-a · Cited by 1,019
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Antidepressants and neuroplasticity
D'Sa, C., & Duman, R. S. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01203.x · Cited by 513 · cited 1×
“These long-term effects are thought to involve increases in neural plasticity and growth-related events (”
Background
Research works printed but not linked: 2
- Hirschfeld R, Weisssman M (2002). Risk factors for major depression and bipolar disorder. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 1018–1025.
- Merikangas K, Pine D (2002). Genetic and other vulnerability factors for anxiety and stress disorders. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 868–882.
Cited by
Items 101–200 of 693
Navailles, S., Hof, P. R., & Schmauss, C. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21775 · Cited by 97
“…of fluoxetine, two of which (10 and 16 mg/kg/day in drinking water) have been shown to yield plasma levels that are similar to those achieved with clinically effective doses of fluoxetine (Prozac), and the third dose (25 mg/kg/day) yields plasma levels that are 3 times higher (Dulawa et al., 2004).”
InfluentialProgress in understanding mood disorders: optogenetic dissection of neural circuits
Lammel, S., Tye, K. M., & Warden, M. R. (2014) · Genes, Brain and Behavior · doi:10.1111/gbb.12049 · Cited by 98
“Although weeks of administration are required for mood changes in depressed patients, some rodent studies have showed an acute (Cryan et al. 2002a) or subchronic effect (Dulawa et al. 2004) of high doses of fluoxetine on FST immobility.”
BackgroundResultWarden, S. J., Robling, A. G., Haney, E. M., Turner, C. H., & Bliziotes, M. M. (2010) · Bone · doi:10.1016/j.bone.2009.06.029 · Cited by 95
“An established central effect of gene- and pharmacological-mediated inhibition of the 5-HTT in mice is heightened anxiety-like behavior, which manifests in a hypoactive locomotor behavioral phenotype [33,34].”
BackgroundCurley, J. P., Jensen, C. L., Franks, B., & Champagne, F. A. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.01.013 · Cited by 92
“Data from the final open-field test is typically considered to be more indicative of trait anxiety than data from the first open-field test (Time 1) (Adams and Geyer, 1986; Dulawa et al., 2004).”
MethodComparison of neurogenic effects of fluoxetine, duloxetine and running in mice
Marlatt, M. W., Lucassen, P. J., & van Praag, H. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.086 · Cited by 96
Lyte, M., Daniels, K. M., & Schmitz-Esser, S. (2019) · PeerJ · doi:10.7717/peerj.6199 · Cited by 89
“This dosage, as previously discussed in the ‘Materials and Methods’ section, was chosen based upon a landmark study examining the dose response relationship of chronic per oral administration in three strains of mice and its ability to influence models of anxiety and depression (Dulawa et al., 2004).”
BackgroundMethodResultInfluentialFukumoto, K., Iijima, M., Funakoshi, T., & Chaki, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx116 · Cited by 90
Norcross, M., Poonam, M., Enoch, A. J., Karlsson, R.-M., Brigman, J. L., Cameron, H. A., Harvey-White, J., & Holmes, A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1215-7 · Cited by 88
“…fall on the high and low ends of the spectrum of trait anxiety-like behavior and stress-reactivity, respectively, and that BALB/c are also relatively more sensitive to the behavioral actions of antidepressants (Anisman et al. 2001; Belzung and Griebel 2001; Dulawa et al. 2004; Holmes et al. 2005).”
InfluentialSerotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis
Li, B., Elsten-Brown, J., Li, M., Zhu, E., Li, Z., Chen, Y., Kang, E., Ma, F., Chiang, J., Li, Y.-R., et al. (2025) · Cell · doi:10.1016/j.cell.2025.04.032 · Cited by 103
Fuzi polysaccharide-1 produces antidepressant-like effects in mice
Yan, H., Qu, H.-D., Sun, L., Li, S.-J., Cao, X., Fang, Y., Jie, W., Bean, J. C., Wu, W.-K., Zhu, X., et al. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990733 · Cited by 94
“In the FST, ADs have been shown to reduce the duration of immobility when mice are placed in a container filled with water (Dulawa et al. 2004 ; Porsolt et al. 1977).”
BackgroundAntidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats
Carr, G. V., Schechter, L. E., & Lucki, I. (2011) · Psychopharmacology · doi:10.1007/s00213-010-1798-7 · Cited by 85
“…decreased approach latency in the NIH test, effects that are similar to those of established anti-anxiety drugs (Treit et al. 1981; Bodnoff et al. 1989) and chronic treatment with antidepressants in these tests (Bechtholt et al. 2008; Bodnoff et al. 1988; Bondi et al. 2007; Dulawa et al. 2004).”
BackgroundNeurogenesis in neurological and psychiatric diseases and brain injury: From bench to bedside
Ruan, L., Lau, B. W.-M., Wang, J., Huang, L., Zhuge, Q., Wang, B. Z., Jin, K., & So, K. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.12.006 · Cited by 93
“Application of the stress hormone corticosterone in a noveltysuppressed feeding paradigm, social defeat paradigm, and an unpredictable chronic mild stress paradigm are common methods used to induce anxiety in animal studies (Berton et al., 2006; Santarelli et al., 2003; Dulawa et al., 2004).”
MethodTheodoridi, A., Tsalafouta, A., & Pavlidis, M. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00223 · Cited by 95
“As it has been shown that chronic administration of fluoxetine has an anxiolytic effect on zebrafish (Dulawa et al., 2004; Egan et al., 2009; Wong et al., 2013), the drug could be used as a neuropharmacological tool to modify social stress experienced by zebrafish.”
BackgroundBDNF-restricted knockout mice as an animal model for aggression
Ito, W., Chehab, M., Thakur, S., Li, J., & Morozov, A. (2011) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2010.00676.x · Cited by 84
“The open field test (Denenberg & Morton 1962) was performed essentially as described (Dulawa et al. 2004) in 70 × 70 cm plastic boxes.”
MethodEffects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice
Falcon, E., Maier, K., Robinson, S. A., Hill-Smith, T. E., & Lucki, I. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3723-y · Cited by 84
“The NIH test is an anxiety-like behavior test in rodents that is sensitive to the anxiolytic effects of antidepressants emerging following chronic treatment for weeks, but not following subchronic or acute treatments (Dulawa et al. 2004; Dulawa and Hen 2005; Bechtolt et al. 2008; Balu et al. 2009).”
Maulvault, A. L., Santos, L. H. M. L. M., Paula, J. R., Camacho, C., Pissarra, V., Fogaça, F. H. D. S., Barbosa, V., Alves, R., Pousão‐Ferreira, P., Barceló, ., et al. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.04.015 · Cited by 93
Kvarta, M. D., Bradbrook, K. E., Dantrassy, H. M., Bailey, A. M., & Thompson, S. M. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00359.2015 · Cited by 86
“These tests are sensitive to chronic, but not acute, selective serotonin reuptake inhibitor (SSRI) administration (Dulawa et al. 2004).”
BackgroundMartin, J. M., Bertram, M. G., Saaristo, M., Fursdon, J. B., Hannington, S. L., Brooks, B. W., Burket, S. R., Molé, R. A., Deal, N. D. S., & Wong, B. B. M. (2019) · Environmental Science & Technology · doi:10.1021/acs.est.9b00944 · Cited by 91
Ansai, S., Hosokawa, H., Maegawa, S., & Kinoshita, M. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.050 · Cited by 92
The p75 neurotrophin receptor regulates hippocampal neurogenesis and related behaviours
Catts, V. S., Al‐Menhali, N., Burne, T. H. J., Colditz, M. J., & Coulson, E. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06390.x · Cited by 85
“…as novelty-suppressed feeding is the only depression-like test we used in which mice consistently respond to chronic antidepressive administration (Dulawa et al., 2004; Jacobson & Cryan, 2007), it remains possible that the reduced neurogenesis in p75NTR) ⁄ ) animals underpins this behaviour, but…”
MethodGenetic Regulation of Behavioral and Neuronal Responses to Fluoxetine
Miller, B. H., Schultz, L. E., Gulati, A. D., Cameron, M. D., & Pletcher, M. T. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301497 · Cited by 93
“2.2 (Applied Biosystems).”
BackgroundInfluentialIncrease in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats
Marcussen, A. B., Flagstad, P., Kristjansen, P. E. G., Johansen, F. F., & Englund, U. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00910.x · Cited by 82
“(19) reported that fluoxetine had a chronic, but not subchronic effect on behaviour using different test paradigms in mice (19).”
BackgroundBailey, M. T., Kinsey, S. G., Padgett, D. A., Sheridan, J. F., & Leblebicioglu, B. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.06.013 · Cited by 84
“These effects are reversed by anxiolytic compounds [35].”
BackgroundPharmacomimetics of Exercise: Novel Approaches for Hippocampally- Targeted Neuroprotective Agents
Stranahan, A., Zhou, Y., Martin, B., & Maudsley, S. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709789878292 · Cited by 83
Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory
Hartley, C. A., McKenna, M. C., Salman, R., Holmes, A., Casey, B. J., Phelps, E. A., & Glatt, C. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202044109 · Cited by 82
“plasma levels and anxiolytic behavioral effects (25).”
BackgroundMethodInfluentialHolleran, K. M., Wilson, H. H., Fetterly, T. L., Bluett, R. J., Centanni, S. W., Gilfarb, R. A., Rocco, L. E. R., Patel, S., & Winder, D. G. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.3 · Cited by 86
Warden, S. J., Nelson, I. R., Fuchs, R. K., Bliziotes, M. M., & Turner, C. H. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318173566b · Cited by 83
Retinoid X Receptor Gamma Control of Affective Behaviors Involves Dopaminergic Signaling in Mice
Krzyżosiak, A., Szyszka-Niagolov, M., Wietrzych, M., Gobaille, S., Muramatsu, S., & Krężel, W. (2010) · Neuron · doi:10.1016/j.neuron.2010.05.004 · Cited by 89
Li, Y., Pehrson, A. L., Budac, D. P., Sánchez, C., & Gulinello, M. E. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.06.034 · Cited by 90
Paradoxical Anxiogenic Response of Juvenile Mice to Fluoxetine
Oh, J.-E., Zupan, B., Gross, S., & Toth, M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.47 · Cited by 81
Infant maternal separation impairs adult cognitive performance in BALB/cJ mice
Wang, L., Jiao, J., & Dulawa, S. C. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2209-4 · Cited by 85
“1996; Dulawa et al. 2004). 208 Psychopharmacology (2011) 216:207–218”
BackgroundMethodInfluentialSelf-citationHuang, G.-J., Bannerman, D. M., & Flint, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002104 · Cited by 86
Loss of eIF4E Phosphorylation Engenders Depression-like Behaviors via Selective mRNA Translation
Amorim, I. S., Kedia, S., Kouloulia, S., Simbriger, K., Gantois, I., Jafarnejad, S. M., Li, Y., Kampaite, A., Pooters, T., Romanò, N., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2673-17.2018 · Cited by 85
“Chronic fluoxetine treatment does not rescue depression-like behaviors in 4Eki mice Chronic fluoxetine treatment induced phosphorylation of eIF4E at Ser209 (Dagestad et al., 2006) and alleviated depression-like pheno- types in mice (Dulawa et al., 2004).”
BackgroundResultTan, X., Du, X., Jiang, Y., Botchway, B. O. A., Hu, Z., & Fang, M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00434 · Cited by 79
“Fluoxetine and normal saline were administered from postnatal day 7 (P7) to postnatal day 28 (P28) at a dose of 18 mg/kg/d (18).”
BackgroundHippocampal HDAC4 Contributes to Postnatal Fluoxetine-Evoked Depression-Like Behavior
Sarkar, A., Chachra, P., Kennedy, P., Pena, C. J., Desouza, L. A., Nestler, E. J., & Vaidya, V. A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.73 · Cited by 79
“In contrast, adult fluoxetine (AFlx) induces antidepressant and anxiolytic responses in patients (Brambilla et al, 2005; Olivier et al, 2011) and animal models (Dulawa et al, 2004).”
BackgroundMethodLi, Y., Abdourahman, A., Tamm, J. A., Pehrson, A. L., Sánchez, C., & Gulinello, M. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.05.013 · Cited by 79
Leconte, C., Bihel, E., Lepelletier, F.-X., Bouët, V., Saulnier, R., Petit, E., Boulouard, M., Bernaudin, M., & Schumann‐Bard, P. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.09.025 · Cited by 84
Girgenti, M. J., Hunsberger, J. G., Duman, C. H., Sathyanesan, M., Terwilliger, R. Z., & Newton, S. S. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.005 · Cited by 83
Meijide, F. J., Cuña, R. H. D., Prieto, J. P., Dorelle, L. S., Babay, P. A., & Nostro, F. L. L. (2018) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2018.07.085 · Cited by 84
“Fluoxetine (FLX) is an antidepressant commonly used for the treatment of human depression and anxiety disorders (Dulawa et al., 2004; Milea et al., 2010), and one of the world's most widely prescribed psychoactive drugs (Mennigen et al.”
BackgroundCharacterization of an alcohol addiction‐prone phenotype in mice
Radwańska, K., & Kaczmarek, L. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00394.x · Cited by 82
“…test to differ as far as anxiety, novelty seeking, impulsivity, motivation for sucrose and alcohol preference are concerned (Buselmaier et al. 1981; Belzung & Griebel 2001; Andersen, Dumont & Teicher 2002; Dulawa et al. 2004; Otobe & Makino 2004; Millstein & Holmes 2007; Norcross et al. 2008).”
BackgroundMartinović, J., Todorović, N., Tomanović, N., Bošković, M., Djordjević, S., Pašti, T. D. L., Bernardi, R. E., Djurdjevic, A., & Filipović, D. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.04.010 · Cited by 79
“For the 15 mg/kg/day of fluoxetine in fluoxetine-treated controls, serum concentrations were 280 ± 50 ng/ml, while in chronically-isolated animals they were in the range of 203 ± 28 ng/ml, similar to those reported in human patients treated with therapeutically effective doses of 20–80 mg/day Prozac (100–700 ng/ml) (D…”
BackgroundPopa, D., Cerdan, J., Repérant, C., Guiard, B. P., Guilloux, J., David, D. J. P., & Gardier, A. M. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.037 · Cited by 82
“Oral fluoxetine hydrochloride (Lilly Research Laboratories, Indianapolis) was chronically administered in the drinking water for 4 weeks (160 mg/l of water), corresponding to 18 mg/kg/day, changed weekly (Santarelli et al., 2003; Dulawa et al., 2004) to mice that have been surgically prepared with guide cannula affixe…”
BackgroundMethodInfluentialPredictive validity of a non-induced mouse model of compulsive-like behavior
Greene-Schloesser, D. M., van der Zee, E. A., Sheppard, D. K., Castillo, M. R., Gregg, K. A., Burrow, T., Foltz, H., Slater, M., & Bult‐Ito, A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.02.010 · Cited by 86
“Pharmacological treatments In order to provide better validity, the following experiments used chronic oral drug delivery via drinking water (Boscarino and Parfitt, 2002; Kobayashi et al., 2008; Dulawa et al., 2004).”
5-HT2C receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice
Hackler, E., Airey, D. C., Shannon, C. C., Sodhi, M., & Sanders‐Bush, E. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.02.005 · Cited by 79
Implication of 5-HT2B receptors in the serotonin syndrome
Diaz, S. L., & Maroteaux, L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.025 · Cited by 80
“Additionally, 129/SvPas mice are frequently described as a non- or weaklyresponsive strain in these behavioural tests (Urani et al, 2005; Dulawa et al., 2004).”
BackgroundAntidepressant-like responses to lithium in genetically diverse mouse strains
Can, A., Blackwell, R. A., Piantadosi, S. C., Dao, D. T., O’Donnell, K. C., & Gould, T. D. (2011) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2011.00682.x · Cited by 77
“Identifying differences in behavioral responses between standard mouse strains has been a widely used approach to investigate various antidepressants (Bai et al. 2001; Cervo et al. 2005; Crowley et al. 2005; David et al. 2003; Dubocovich et al. 1990; Dulawa et al. 2004; Liu & Gershenfeld 2001; Lucki et al. 2001; Nomur…”
BackgroundDifferential effects of acute and repeated citalopram in mouse models of anxiety and depression
Mombereau, C., Gur, T. L., Onksen, J., & Blendy, J. A. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990630 · Cited by 73
“1995), novelty-induced hypophagia (NIH; Dulawa et al. 2004), and the mouse defensive test battery (Griebel et al.”
InfluentialRGS inhibition at Gαi2selectively potentiates 5-HT1A–mediated antidepressant effects
Talbot, J. N., Jutkiewicz, E. M., Graves, S. M., Clemans, C. F., Nicol, M. R., Mortensen, R. M., Huang, X., Neubig, R. R., & Traynor, J. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000003107 · Cited by 72
“These behaviors are similar to those observed in mice treated with chronic but not acute fluoxetine (19, 20).”
BackgroundResultBradaschia-Corrêa, V., Josephson, A. M., Mehta, D. D., Mizrahi, M. M., Neibart, S. S., Liu, C., Kennedy, O. D., Castillo, A. B., Egol, K. A., & Leucht, P. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3045 · Cited by 77
“Therefore, we first utilized a murine model of endochondral ossification to study the effect of chronic fluoxetine use((9)) on this mode of repair.”
MethodInfluentialShanahan, N. A., Velez, L. P., Masten, V. L., & Dulawa, S. C. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.07.032 · Cited by 72
Self-citationAquatic blues: Modeling depression and antidepressant action in zebrafish
Nguyen, M., Stewart, A., & Kalueff, A. V. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.03.003 · Cited by 77
Effect of Antidepressant Drugs in Mice Lacking the Norepinephrine Transporter
Dziedzicka‐Wasylewska, M., Faron‐Górecka, A., Kuśmider, M., Drozdowska, E., Rogóż, Z., Siwanowicz, J., Caron, M. G., & Bönisch, H. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301064 · Cited by 77
“However, some studies have shown that subchronic or acute effects were increased by chronic pre-administration of the AD (Borsini and Meli, 1988; Conti et al, 2002; Dulawa et al, 2004).”
BackgroundReinés, A. G., Cereseto, M., Ferrero, A., Sifonios, L. L., Podestá, M. F., & Wikinski, S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301596 · Cited by 74
“In the present work, we show that when LH animals are chronically treated with FLX for 21 days, as expected from other reports (Dulawa et al, 2004), reversion of depressivelike behavior is observed.”
BackgroundKobayashi, K., Ikeda, Y., Haneda, E., & Suzuki, H. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1656-08.2008 · Cited by 70
“Dulawa et al. (2004) also showed that the chronic oral fluoxetine treatment at the same dose as used in our study did not affect the depression-related behavior in C57BL/6 mice, but caused a reduction in the open-field activity, although it was less ob- vious than the effect observed in our study.”
BackgroundMethodResultInfluentialSarkar, A., Chachra, P., & Vaidya, V. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.005 · Cited by 74
“humans (16) and in rodents (17), following fluoxetine administration in adulthood.”
BackgroundSocial instability is an effective chronic stress paradigm for both male and female mice
Yohn, C. N., Ashamalla, S. A., Bokka, L., Gergues, M. M., Garino, A., & Samuels, B. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107780 · Cited by 73
Wietrzych, M., Szyszka-Niagolov, M., Ohta, K., Endo, Y., Pérez‐Santín, E., de Lera, Á. R., Chambon, P., & Krężel, W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.017 · Cited by 71
Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease
Aboukhatwa, M., Dosanjh, L., & Luo, Y. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-10 · Cited by 69
“effects seen at acute or subchronic dosing [82].”
BackgroundShen, M., Yang, Y., Wu, Y., Zhang, B., Wu, H., Wang, L., Tang, H., & Chen, J. (2019) · Phytotherapy Research · doi:10.1002/ptr.6237 · Cited by 68
Carr, G. V., & Lucki, I. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1832-9 · Cited by 70
“Anxiolytic compounds reduce the latency to approach food and increase feeding in the NIH test (Bechtholt et al. 2008; Dulawa et al. 2004; Merali et al. 2003).”
Lee, J.-S., Jang, D.-J., Lee, N., Ko, H.-G., Kim, H., Kim, Y.-S., Kim, B., Son, J., Kim, S. H., Chung, H., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1321-09.2009 · Cited by 66
“To assess whether our results on the FST in Ap oa1 mice can be generalized as an antidepressant-like phenotype, a separate group of mice were tested for two depression-related behaviors, the NSFT and the SCT, within a 2 d period 2 weeks after the chronic octopamine or fluoxetine treatment (Fig.”
MethodInfluentialAmigó, J., Díaz, Á., Pilar-Cuéllar, F., Vidal, R., Martín, A., Compan, V., Pazos, Á., & Castro, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.037 · Cited by 68
Zhao, J., Jung, Y.-H., Jang, C.-G., Chun, K.-H., Kwon, S. W., & Lee, J. (2015) · Scientific Reports · doi:10.1038/srep08890 · Cited by 66
Li, K., Shen, S., Ji, Y., Li, X., Zhang, L., & Wang, X. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0189-z · Cited by 70
Rosso, M. E. D., Palumbo, M. L., & Genaro, A. M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.021 · Cited by 67
Cunha, V. F. P. M., Rodrigues, P., Santos, M. M., Moradas-Ferreira, P., & Ferreira, M. (2017) · Chemosphere · doi:10.1016/j.chemosphere.2017.10.100 · Cited by 66
“…66 Fluoxetine (FLU) is one of the most prescribed pharmaceuticals acting as a selective 67 serotonin reuptake inhibitor (SSRI) (Mennigen et al., 2011; Winder et al., 2012) 68 indicated in the treatment of human depression, anxiety, compulsive behaviour and 69 eating disorders (Dulawa et al., 2004).”
BackgroundStress induced cognitive deficit is differentially modulated in BALB/c and C57Bl/6 mice
Palumbo, M. L., Canzobre, M. C., Pascuan, C. G., Ríos, H., Wald, M. R., & Genaro, A. M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.11.005 · Cited by 73
“…stress reactivity; whereas C57BL/6 is considered a nonemotive, non-anxious and active strain in different experimental situations, such as the open-field test or the elevated plus-maze test (Belzung and Griebel, 2001; Marona-Lewicka and Vetulani, 1989; Tang et al., 2002; Dulawa et al., 2004).”
BackgroundCastro, J. E., Varea, E., Márquez, C., Cordero, M. I., Poirier, G., & Sandi, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008618 · Cited by 60
“Forced-swim Test One day after the last fluoxetine treatment, rats were submitted to a forced-swim test to evaluate depression-like behaviors [47,48].”
MethodBirkett, M. A., Shinday, N. M., Kessler, E. J., Meyer, J. S., Ritchie, S., & Rowlett, J. K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.006 · Cited by 59
“…in BALB/c mice, a strain previously shown to be sensitive to anxiogenic-like and anxiolytic-like effects of several classes of drugs (Anisman et al., 2001; Belzung et al., 2001; Bouwknecht and Paylor, 2002; Dulawa et al., 2004; Griebel et al., 2000; Piappert and Pilz, 2002; Roy et al., 2001).”
BackgroundRodent ketamine depression-related research: Finding patterns in a literature of variability
Polis, A. J., Fitzgerald, P. J., Hale, P. J., & Watson, B. O. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112153 · Cited by 67
Kwatra, M., Ahmed, S., Gawali, B., Panda, S. R., & Naidu, V. G. M. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104835 · Cited by 65
Mahar, I., Tan, S., Davoli, M. A., Dominguez-Lopez, S., Qiang, C., Rachalski, A., Turecki, G., & Mechawar, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026610 · Cited by 60
“Treatments that induce neurogenic, antidepressant and anxiolytic effects typically do so after chronic - but not subchronic duration [2,3,17,18,80,81].”
BackgroundKoshkina, A., Dudnichenko, T., Baranenko, D., Fedotova, J., & Drago, F. (2019) · Nutrients · doi:10.3390/nu11081726 · Cited by 68
Li, Y., Raaby, K. F., Sánchez, C., & Gulinello, M. E. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.09.002 · Cited by 66
Fluoxetine Induced Suicidal Erythrocyte Death
Jilani, K., Enkel, S., Bissinger, R., Almilaji, A., Abed, M., & Lang, F. J. W. (2013) · Toxins · doi:10.3390/toxins5071230 · Cited by 61
“The concentrations required to stimulate eryptosis are only moderately higher than the concentrations encountered in vivo [32,33].”
BackgroundBrenes, J. C., Fornaguera, J., & Sequeira‐Cordero, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00804 · Cited by 65
Branchi, I., D’Andrea, I., Cirulli, F., Lipp, H.-P., & Alleva, E. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.10.016 · Cited by 66
“This is line with the notion that acute antidepressant-like effects in the forced swim test are likely to reflect the initial events elicited by the pharmacological treatment rather than the progressive changes that are likely to accompany chronic antidepressant administration (Dulawa et al., 2004).”
BackgroundBalu, D. T., Hodes, G. E., Anderson, B. T., & Lucki, I. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.234 · Cited by 56
“Novelty-induced hypophagia (NIH), which does not require food deprivation, is sensitive to chronic antidepressant treatments in a number of mouse strains (Merali et al., 2003; Dulawa et al., 2004; Gur et al., 2007).”
Haj‐Mirzaian, A., Ostadhadi, S., Kordjazy, N., Dehpour, A. R., & Mehr, S. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.03.053 · Cited by 60
Armario, A., & Nadal, R. A. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00137 · Cited by 66
“…between laboratories in the FST behavior of particular outbred and inbred mice either in drug-free conditions or in response to antidepressants (Lucki et al., 2001; Ventura et al., 2002; David et al., 2003; Dulawa et al., 2004; Cervo et al., 2005; Guzzetti et al., 2008; Sugimoto et al., 2008).”
BackgroundPiras, G., Giorgi, O., & Corda, M. G. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1904-x · Cited by 64
“A number of reports, however, have shown effects of antidepressant drugs in the forced swim test after chronic treatment with doses that were inactive when given acutely (Dulawa et al. 2004; Cryan et al. 2005a; Pucilowski and Overstreet 1993).”
BackgroundDeltheil, T., Tanaka, K., Reperant, C., Hen, R., David, D. J., & Gardier, A. M. (2009) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000017 · Cited by 54
Self-citationAliko, V., Mehmeti, E., Qirjo, M., & Faggio, C. (2019) · Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale · doi:10.4081/jbr.2019.7939 · Cited by 58
Rodent models of treatment-resistant depression
Caldarone, B. J., Zachariou, V., & King, S. L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.063 · Cited by 50
“…antidepressant efficacy: C57BL/6J mice were not responsive to acute (Castagne et al., 2009; Lucki et al., 2001) or chronic fluoxetine in the FST (Dulawa et al., 2004) or novelty-induced hypophagia test (Balu et al., 2009); acute fluvoxamine had no effect in C57BL/6Cr mice in the FST (Sugimoto…”
BackgroundDoosti, M.-H., Bakhtiari, A., Zare, P., Amani, M., Majidi-Zolbanin, N., Babri, S., & Salari, A.-A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.003 · Cited by 56
Warden, S. J., Hassett, S. M., Bond, J. L., Rydberg, J., Grogg, J. D., Hilles, E. L., Bogenschutz, E. D., Smith, H. D., Fuchs, R. K., Bliziotes, M. M., et al. (2010) · Bone · doi:10.1016/j.bone.2009.12.031 · Cited by 55
“In addition, they have previously been shown to have anti-anxiolytic [28,29] and skeletal effects [23–25] in mice at the doses administered.”
BackgroundOlanzapine, but Not Fluoxetine, Treatment Increases Survival in Activity-Based Anorexia in Mice
Klenotich, S. J., Seiglie, M. P., McMurray, M. S., Roitman, J. D., Grange, D. L., Dugad, P., & Dulawa, S. C. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.7 · Cited by 58
“Subchronic OLZ treatment (12 mg/kg/day) and chronic OLZ treatment (8 mg/kg/day, 16 mg/kg/day) produced OLZ plasma levels (Supplementary Figure S7, S8) that are above the threshold, which predicts a therapeutic response in patients with schizophrenia (Perry et al, 2001).”
BackgroundResultSelf-citationGardier, A. M. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283243fcd · Cited by 54
“In particular, while they produce a relatively fast blockade of the 5-HT transporter (SERT) in vitro, the onset of an appreciable antidepressant-like effect in vivo is slow, taking several weeks to occur in humans (Katz et al., 2004) as well as in animals (Dulawa et al., 2004).”
BackgroundCaffin, F., Prola, A., Piquereau, J., Novotova, M., David, D. J., Garnier, A., Fortin, D., Alavi, M. V., Veksler, V., Ventura‐Clapier, R., et al. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.263079 · Cited by 55
“This test was performed as described previously (Dulawa et al. 2004).”
MethodMice undergoing neuropathic pain induce anxiogenic-like effects and hypernociception in cagemates
Baptista-de-Souza, D., Nunciato, A. C., Pereira, B. C., Fachinni, G., Zaniboni, C. R., & Canto-de-Souza, A. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000170 · Cited by 55
“…for the latency to stop swimming and the total time of immobility, where the animal passively floated with its head above the water surface, with small movements to maintain this position (Porsolt et al., 1977; Abel et al., 1992; Barros and Ferigolo, 1998; Hirani et al., 2002; Dulawa et al., 2004).”
BackgroundMethodGasmi, S., Rouabhi, R., Kebieche, M., Boussekine, S., Aya, S., Nadjiba, T., Taib, C., Bouteraa, Z., Hajer, C., Henine, S., et al. (2017) · Environmental Science and Pollution Research · doi:10.1007/s11356-017-9218-8 · Cited by 58
“…ATP leading to a decrease in the viability of neurons and also increased cell degeneration in hippocampus and striatum caused physiological and behavioral disturbance in rats treated with DLM (Dulawa et al. 2004; Galal et al. 2014; Ekaluo et al. 2013; Kumar et al. 2015; Utip et al. 2013).”
BackgroundDadomo, H., Sanghez, V., Di Cristo, L., Lori, A., Ceresini, G., Malinge, I., Parmigiani, S., Palanza, P., Sheardown, M., & Bartolomucci, A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.016 · Cited by 54
Kutiyanawalla, A., Terry, A. V., & Pillai, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026153 · Cited by 57
“mice) are known to respond poor in open filed activity to antidepressant treatments [18], we next tested the anxiety”
Ihne, J. L., Fitzgerald, P. J., Hefner, K. R., & Holmes, A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.045 · Cited by 52
“Chronic treatments typically produce anxiolytic-like and antidepressant-related effects in BALB/cJ or ′129′ strains, or mixed genetic backgrounds, whereas, similar to our finding, C57BL/6J are often either unresponsive or found to exhibit non-specific sedation (Balu et al., 2009; David et al., 2009; Dulawa et al., 200…”
BackgroundResultInfluentialYoo, S. B., Kim, B. T., Kim, J. Y., Ryu, V., Kang, D. W., Lee, J.-H., & Jahng, J. W. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.013 · Cited by 59
“, 2005), and was proved to maintain the serum fluoxetine levels corresponding to an effective therapeutic dose for depressed patients (Dulawa et al., 2004).”
BackgroundOhira, K., & Miyakawa, T. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-10 · Cited by 53
“We have chosen the concentration of FLX, since serum FLX levels in mice receiving 15 mg/kg/day chronic FLX have been shown to be comparable to those in human patients receiving 20-80 mg FLX (Prozac) per day [54].”
Stewart, A., Maity, B., Wunsch, A. M., Meng, F., Wu, Q., Wemmie, J. A., & Fisher, R. A. (2014) · The FASEB Journal · doi:10.1096/fj.13-235648 · Cited by 53
“Novelty-induced hypophagic behavior was assessed in nonstarved animals placed in home or novel cage environments, as outlined previously (7).”
BackgroundMethodInfluentialEskelund, A., Li, Y., Budac, D. P., Müller, H. K., Gulinello, M., Sanchez, C., & Wegener, G. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14043 · Cited by 52
Poggini, S., Golia, M. T., Alboni, S., Milior, G., Sciarria, L. P., Viglione, A., Matte Bon, G., Brunello, N., Puglisi-Allegra, S., Limatola, C., et al. (2019) · Neural Plasticity · doi:10.1155/2019/4651031 · Cited by 50
“The solutions were prepared according to the mouse average weight and daily water consumption in order to provide an average daily intake of 30mg/kg of FLX [20] and 200mg/kg of MET, respectively [21, 22].”
β-sitosterol reduces anxiety and synergizes with established anxiolytic drugs in mice
Panayotis, N., Freund, P. A., Marvaldi, L., Shalit, T., Brandis, A. S., Mehlman, T., Tsoory, M., & Fainzilber, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100281 · Cited by 65
“A dose-response analysis with fluoxetine showed that doses of 10 mg/kg and above had significant anxiolytic effects in mice, while doses of 5 mg/kg and below had no apparent effect (Figure S3), in agreement with the literature.(34) We then tested the effect of increasing the b-sitosterol dose in mice receiving a sub-e…”
Result
Metadata
- Authors
- Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R.
- Affiliations
- Columbia University (US)
- Venue
- Neuropsychopharmacology
- Published
- 2004-04-07
- Volume
- 29
- Issue
- 7
- Pages
- 1321-1330
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1987972424
- Cited by
- 671
- References
- 50
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 27 · 2023: 28 · 2022: 32 · 2021: 32 · 2020: 31 · 2019: 51 · 2018: 31 · 2017: 42 · 2016: 34 · 2015: 42 · 2014: 41 · 2013: 44 · 2012: 28
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression (MH068542-1)
- National Institutes of Health (5r01da009862-08, 5f32mh065791-02)
- National Institute of Mental Health (F32-MH65791-01A1, P50MH050733, P50-MH50733, R01 MH068542-1, R01MH068542)
- National Institute on Drug Abuse (R01 DA09862)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- fluoxetine, chronic antidepressant treatment, anxiety, depression, selective serotonin reuptake inhibitors, inbred mouse strains, BALB/c mice, forced swim test, novelty-induced hypophagia, locomotor activity, antidepressant sensitivity
- MeSH terms
- Analysis of Variance, Animals, Anxiety, Behavior, Animal, Depression, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Administration Schedule, Exploratory Behavior, Fluoxetine, Immobilization, Male, Mice, Inbred Strains, Motor Activity, Reaction Time, Species Specificity, Swimming, Time Factors, Selective Serotonin Reuptake Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.